MeSH tree: D27.505.954.248.794
A phase 1 study aiming to test tolerability of combination therapy with trastuzumab deruxtecan and olaparib in Human Epidermal Growth Factor Receptor 2 (HER2)-expressing malignancies—including ovarian and uterine cancers—found ...
Apr 20, 2026
0
4
Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug conjugate (ADC) QLS5132, according ...
Apr 20, 2026
0
6
New research published in Nature Communications has linked a normal cellular process to an accumulation of DNA mutations in cancer and identified cancer-driving mutations in an underexplored part of the genome.
Dec 4, 2025
0
34
A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrates encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), according to findings presented ...
Sep 6, 2025
0
25
